ABUS vs. ALNY
Compare and contrast key facts about Arbutus Biopharma Corporation (ABUS) and Alnylam Pharmaceuticals, Inc. (ALNY).
Performance
ABUS vs. ALNY - Performance Comparison
Loading graphics...
ABUS vs. ALNY - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
ABUS Arbutus Biopharma Corporation | -6.44% | 47.09% | 30.80% | 7.30% | -40.10% | 9.58% | 27.70% | -27.42% | -24.16% | 106.12% |
ALNY Alnylam Pharmaceuticals, Inc. | -17.33% | 68.99% | 22.94% | -19.46% | 40.14% | 30.48% | 12.85% | 57.96% | -42.61% | 239.34% |
Fundamentals
ABUS:
$862.20M
ALNY:
$44.80B
ABUS:
-$0.17
ALNY:
$2.33
ABUS:
61.33
ALNY:
11.90
ABUS:
11.26
ALNY:
56.77
ABUS:
$14.08M
ALNY:
$3.71B
ABUS:
$400.00K
ALNY:
$3.04B
ABUS:
-$38.16M
ALNY:
$472.68M
Returns By Period
In the year-to-date period, ABUS achieves a -6.44% return, which is significantly higher than ALNY's -17.33% return. Over the past 10 years, ABUS has underperformed ALNY with an annualized return of 0.76%, while ALNY has yielded a comparatively higher 17.63% annualized return.
ABUS
- 1D
- 4.65%
- 1M
- -3.43%
- YTD
- -6.44%
- 6M
- -0.88%
- 1Y
- 28.94%
- 3Y*
- 14.09%
- 5Y*
- 5.58%
- 10Y*
- 0.76%
ALNY
- 1D
- -0.65%
- 1M
- 1.13%
- YTD
- -17.33%
- 6M
- -28.64%
- 1Y
- 28.53%
- 3Y*
- 17.95%
- 5Y*
- 18.31%
- 10Y*
- 17.63%
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
ABUS vs. ALNY — Risk / Return Rank
ABUS
ALNY
ABUS vs. ALNY - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Arbutus Biopharma Corporation (ABUS) and Alnylam Pharmaceuticals, Inc. (ALNY). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| ABUS | ALNY | Difference | |
|---|---|---|---|
Sharpe ratioReturn per unit of total volatility | 0.60 | 0.70 | -0.10 |
Sortino ratioReturn per unit of downside risk | 1.09 | 1.24 | -0.15 |
Omega ratioGain probability vs. loss probability | 1.14 | 1.16 | -0.02 |
Calmar ratioReturn relative to maximum drawdown | 1.10 | 0.58 | +0.53 |
Martin ratioReturn relative to average drawdown | 2.90 | 1.29 | +1.61 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading graphics...
Sharpe Ratios by Period
| ABUS | ALNY | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | 0.60 | 0.70 | -0.10 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | 0.10 | 0.38 | -0.28 |
Sharpe Ratio (10Y)Calculated over the trailing 10-year period | 0.01 | 0.33 | -0.32 |
Sharpe Ratio (All Time)Calculated using the full available price history | -0.09 | 0.34 | -0.43 |
Correlation
The correlation between ABUS and ALNY is 0.32, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.
Dividends
ABUS vs. ALNY - Dividend Comparison
Neither ABUS nor ALNY has paid dividends to shareholders.
Drawdowns
ABUS vs. ALNY - Drawdown Comparison
The maximum ABUS drawdown since its inception was -92.96%, which is greater than ALNY's maximum drawdown of -83.58%. Use the drawdown chart below to compare losses from any high point for ABUS and ALNY.
Loading graphics...
Drawdown Indicators
| ABUS | ALNY | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -92.96% | -83.58% | -9.38% |
Max Drawdown (1Y)Largest decline over 1 year | -25.86% | -37.57% | +11.71% |
Max Drawdown (5Y)Largest decline over 5 years | -63.42% | -42.46% | -20.96% |
Max Drawdown (10Y)Largest decline over 10 years | -92.96% | -59.95% | -33.01% |
Current DrawdownCurrent decline from peak | -63.56% | -33.08% | -30.48% |
Average DrawdownAverage peak-to-trough decline | -68.84% | -30.53% | -38.31% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 9.87% | 16.88% | -7.01% |
Volatility
ABUS vs. ALNY - Volatility Comparison
Arbutus Biopharma Corporation (ABUS) has a higher volatility of 15.46% compared to Alnylam Pharmaceuticals, Inc. (ALNY) at 10.30%. This indicates that ABUS's price experiences larger fluctuations and is considered to be riskier than ALNY based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading graphics...
Volatility by Period
| ABUS | ALNY | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 15.46% | 10.30% | +5.16% |
Volatility (6M)Calculated over the trailing 6-month period | 36.75% | 25.83% | +10.92% |
Volatility (1Y)Calculated over the trailing 1-year period | 48.45% | 41.46% | +6.99% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 55.58% | 48.70% | +6.88% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 85.72% | 54.24% | +31.48% |
Financials
ABUS vs. ALNY - Financials Comparison
This section allows you to compare key financial metrics between Arbutus Biopharma Corporation and Alnylam Pharmaceuticals, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities